Effective September 10, 2020, lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg, (Temixys™) has been added to the ADAP formulary. Temixys™ is a combination of two nucleoside analog reverse transcriptase inhibitors. Temixys™ is a once-daily single-tablet combination regimen used for the treatment of HIV-1 infection in combination with other antiretroviral medications. Temixys™ received federal Food and Drug Administration (FDA) approval in November 2018; however, it was not available in the U.S. until the last quarter of 2019. Temixys™ contains the same ingredients as Cimduo™, which is already on the ADAP formulary. The addition of Temixys™ will ensure that ADAP clients are not denied coverage due to the version of lamivudine/tenofovir disoproxil fumarate that is dispensed.
If you have any questions regarding the addition of this medication to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health